VIDEO: PER-001 offers new mechanism of action to treat diabetic retinopathy

LONG BEACH, Calif. — In this video from the American Society of Retina Specialists annual meeting, Arshad M. Khanani, MD, MA, FASRS, discusses PER-001, an endothelin antagonist from Perfuse Therapeutics, for diabetic retinopathy.“This is a really exciting new mechanism of action for our field, hoping to improve functional as well as structural outcomes for our patients with diabetic